HIV-1 protease-IN-8

• UNSPSC Description:

  HIV-1 protease-IN-8 (compound 34b) is a potent HIV-1 protease inhibitor with an IC50 value of 0.32 nM. HIV-1 protease-IN-8 displays IC50s of 0.29 μM and 1.90 μM for wild-type HIV-1 (HIV-1NL4-3) and drug-resistant variant (HIV-1MDR), respectively. HIV-1 protease-IN-8 displays robust antiviral activity against both wild-type HIV-1 and drug-resistant variant[1].

• Target Antigen:

  HIV Protease

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/hiv-1-protease-in-8.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(C2=CC=C(C=C2)O)=O)[C@@H]3CCNC3

• Molecular Weight:

  489.63

• References & Citations:

  [1]Huiyu Zhou, et al. Design, synthesis, and biological evaluation of novel HIV-1 protease inhibitors containing pyrrolidine-derived P2 ligands to combat drug-resistant variant. Eur J Med Chem. 2023 Jul 5;255:115389.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2925287-55-2